REVIEW

The eyelash follicle features and anomalies: A review

Sarah Aumond*, Etty Bitton

École d’optométrie, Université de Montréal, 3744 Rue Jean-Brillant, Montréal, Québec, Canada H3T 1P1

Received 31 January 2018; accepted 26 May 2018
Available online 17 July 2018

KEYWORDS
Eyelash; Follicle; Hair; Eyelash pathophysiology; Lid margin

Abstract   The primary role of eyelashes is to protect and maintain the health of the lid margin. However, the mechanisms to fulfill this role are not fully understood. Unraveling these mechanisms will stand to greatly improve the efficiency of eye care professionals’ interventions in anomalies of the eyelashes. The aim of this article is to provide a review on eyelashes including highlights and new avenues for research; the biology of both the lash and its follicle; the pathophysiology and management of lash anomalies by eye care professionals; and the effect of iatrogenic factors on lashes. Using the database of Ovid MEDLINE, we reviewed studies specifically directed on human/mammalian eyelashes and key articles on current trends in scalp hair methodologies that can be applicable to lash research. The eyelash morphology, pigmentation and growth rate have been documented using techniques ranging from lash imaging to follicle immunohistochemistry. Furthermore, studies have demonstrated that the lash follicle is sensitive to many factors of the external environment, a variety of systemic/topical medications and cosmetics. Recently, aerodynamic studies using a mammalian eye model confirmed that an optimal lash length was needed so that eyelashes serve a protective role in reducing the number of particles that can reach the eye. Despite recent advances in lash research, studies are still scarce, due to the limited availability of the human lid for sampling. This review brings awareness that further research is needed with respect to eyelashes and will hopefully reduce the gap with scalp hair research.

© 2018 Spanish General Council of Optometry. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PALABRAS CLAVE
Pestañas; Foliculo; Pelo; Patofisiología de las pestañas; Margen palpbral

Características y anomalías del folículo de la pestaña: revisión

Resumen   La función principal de las pestañas es proteger y mantener la salud del margen palpebral. Sin embargo, los mecanismos de desempeño de esta función no se comprenden plenamente. Desentrañar estos mecanismos ayudará a mejorar la eficiencia de las intervenciones de los profesionales de cuidados oculares en cuanto a las anomalías de las pestañas. El objetivo de este artículo es aportar una revisión sobre las pestañas, incluyendo los aspectos

* Corresponding author at: École d’optométrie, Université de Montréal, 3744 Rue Jean-Brillant, Montréal, Québec, Canada H3T 1P1.
E-mail address: sarah.aumond@umontreal.ca (S. Aumond).

https://doi.org/10.1016/j.optom.2018.05.003
1888-4296/© 2018 Spanish General Council of Optometry. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Little research has been done on the human eyelash on account that most of the attention has been directed to research on hair for people suffering from scalp hair loss. However, recent discoveries on the role of eyelashes and its distinctive characteristics have led to an increased scientific interest. Moreover, eyelashes are now considered an important aspect of the facial esthetic and are the object of various beauty treatments to enhance them.1,2 Since eyelashes form a barrier between the external and internal environment of the eye, they are extremely sensitive to a variety of threats and irritants and are highly innervated to perform that function.3 Eyelashes are an integral part of the lid margin anatomy, much like the Meibomian glands, eyelid skin and biofilm, each contributing to the overall homeostasis of the ocular surface. As such, it is important to maintain their integrity. As a whole, the lid margin is responsible for the production of the tear film lipid layer and the protection of the eye from external trauma. Via the blink, it distributes the tears toward the nasolacrimal puncta found in the inner portion of the lid margin.4 If any part of the lid margin is inflamed, it can induce a tear film disturbance or instability which can, in turn, affect the ocular surface.5 Left untreated, this inflammatory cascade can develop into dry eye disease.6 Therefore, studying the eyelash and its pathophysiology is valuable for researchers and eye care professionals (ECPs) alike, to maintain ocular surface homeostasis.

An Ovid MEDLINE search for eyelash physiopathology/abnormalities/pathologies has led to 419 human and 59 non-human publications. The articles that were selected for this non-systematic review concentrated on the general biology of the human lash, the prevailing methods in lash research, lash anomalies and the resulting pathologies with their associated clinical management by an ECP. Also, we reviewed relevant articles on current trends in scalp hair research that can be applicable to eyelashes, and the iatrogenic factors that can affect the lashes, such as cosmetics.

The general biology of the human lash

The human lower lid contains 75–80 lashes dispersed in three to four rows, whereas the upper lid has 90–160 lashes scattered on five to six rows.4,5 The anatomy of the lash and hair has some similar characteristics.8 Both have a hair shaft (the visible part) that extends outside the skin, a root that is under the skin and a bulb, which is the enlarged terminal portion (Fig. 1). The inferior portion of the bulb is in direct contact with the dermal papilla, which brings key mesenchymal-epithelial interactions in follicle cycling.

The lash itself is made up of three structures that fit into one another (Fig. 2).6 The innermost structure, the medulla, consists of loose cells. A thicker cortex surrounds the medulla to ensure its strength and stability. The pigmentation of either the lash or hair is the result of the melanin contained in the cortex. Finally, the cuticle, composed of several cell layers, forms the outermost portion, offering protection to the internal structures by its impermeability.

The anatomy and physiology of the lash follicle are distinctive from other hair follicles. Consequently, the lash follicle is worthy of a detailed study and appreciation of its specific characteristics and surrounding skin; its influence on the lash life cycle, curvature, and pigmentation; and the age-related changes of the lashes.
The eyelash follicle features and anomalies: A review

Figure 1: The general morphology of the eyelash and its surrounding skin.

Figure 2: The anatomy of the eyelash.

The surrounding skin of the follicle and its features

To appreciate the main characteristics of the lash follicle and its surrounding skin, it is imperative to compare these structures to that of the scalp hair, which have been studied extensively. The scalp skin contains three layers: the epidermis (external), the dermis (middle) and the hypodermis (internal) whereas the skin of the lids has two layers: a thinner epidermis and a dermis. All follicles on the human body are rooted in their deepest skin layer, notably the hypodermis for the scalp and the dermis for the lid. Consequently, the lash follicle is shorter than the scalp hair follicle. Another major characteristic that distinguishes lash follicles from scalp hair follicles is that they have no arrector pili muscles, which are responsible for straightening the hair in response to cold or intense emotions, producing, what is commonly referred to as 'goose bumps'. Therefore, lashes do not require individual mobility.

Lash follicles are connected with two types of secretory glands: Zeiss and Moll. They produce different substances released through channels that flow into the follicle. The Zeiss glands use a holocrine mechanism of action, thus liberating their complete cell content, which is a sebum. It has antimicrobial and lubrication properties, just as it allows the transport of antioxidants, although the exact function of the sebum is unknown. The Moll glands, only found in the lids and active from birth, are apocrine glands that produce secretions by fragmentation from one side of their cells. Their secretions, which contain a variety of sugar components, might play a critical role in the defense against microorganisms.

The life cycle, curvature and pigmentation

Lashes have a life cycle consisting of three phases: the growth phase (anagen), the degradation phase (catagen) and the resting phase (telogen). Following the telogen phase, the lash falls out and the life cycle begins again with a new lash in the anagen phase (Fig. 3). The daily growth rate of a lash is 0.12–0.14 mm. The anagen phase duration varies from four to ten weeks and the complete life cycle is from four to eleven months. The lash length rarely exceeds 12 mm, as the growth rate and anagen phase duration are shorter than the ones observed in scalp hair research. The lash growth rate is influenced by several factors, including the topical prostaglandin analogs used to reduce the intraocular pressure in glaucoma patients. Nesher et al. demonstrated that the prostaglandin analog F2α receptors were expressed in several layers of the lash follicle during its anagen phase. Further studies are needed to confirm the expression of the prostaglandin analog F2α receptors with the use of prostaglandin analogs eyedrops.

The morphology of the eyelashes is such that they are curved in all individuals, regardless of ethnicity. This curvature is initiated at the bulb of the lash and continues until the tip of the shaft. Thibaut et al. have shown that several cell types of the lash follicle alongside the bulb location are asymmetric (i.e. certain sheaths along the concave side of the bulb are thicker than the ones on the convex side). While studying the biology of curly hair in vitro, the same phenomenon of asymmetry has been observed. Curly hair’s markers are also found in the cuticle and cortex of the lash itself. These studies offer possible explanations of the mechanisms involved in lash curvature. Nevertheless, the amplitude of the curvature can vary among individuals. Ethnic studies have identified a difference in the degree of lash curvature (or curl) revealing that the lift-up and curl-up angles are more pronounced among Caucasians as compared to Asians.
The skin and all hair on the human body acquire their pigmentation mostly by melanogenesis, which is the synthesis of different types of melanin by the melanocytes,\textsuperscript{17} these cells being under the influence of several enzymes, including tyrosinase-related protein 2 (TRP-2).\textsuperscript{18} When it comes to lashes, their degree of pigmentation is defined by the quantity of melanocytes in the lash follicle structure.\textsuperscript{9} The lash becomes grayish at a very advanced age and rarely whitens.\textsuperscript{6} The maintenance of the lash pigmentation may be explained by a sustained expression of TRP-2.\textsuperscript{9} Further studies are needed to confirm if this association is a direct cause-effect relationship. In contrast, many studies have shown that scalp hair will progressively lose its pigmentation due to a gradual depletion of melanocytes.\textsuperscript{19} Several mechanisms have been demonstrated to explain this phenomenon: melanocyte apoptosis, oxidative stress and a reduced expression of certain enzymes, such as TRP-2.\textsuperscript{17,20,21}

Age-related changes

There are limited studies about age-related changes on eyelashes. Procionoy et al. have studied women’s lower lid lashes and found that the curvature of the lashes on the medial and central eyelid portion increased with age, while those of the lateral portion remained in the same direction.\textsuperscript{22} Glaser et al. reported that there was a reduction of length, thickness and pigmentation of the lashes with age.\textsuperscript{23}

Research methods

Compared to scalp hair, little research has been dedicated to the study of eyelashes, namely due to the limitation inherent to the in vivo access of the lash follicle. This section explores the techniques employed in lash research and their challenges.

Sampling and organ culture of the lash follicle

There are only a few studies on human lash follicle sampling because it is limited to cadaveric studies and eyelid surgeries, such as ectropion repairs.\textsuperscript{3,9,14} It was in 1969 that the first research on the histology and cytochemistry of human lids and lashes was published.\textsuperscript{3} The function and microscopic anatomy of the follicle cells were studied post mortem following sudden accidental deaths. Other studies that have succeeded in preserving a portion of the human lid have used immunohistochemistry to perform analysis.\textsuperscript{5,14} This technique consists of detecting
certain antigens (proteins) in the cells of the tissue, using antibodies that bind to them specifically. This technique allowed researchers to describe the morphology, curvature and pigmentation of the lash follicles, and the presence and characteristics of some prostaglandin receptors in the follicles.

As sampling on human lash follicles is limited, it is even more complex for scientists to perform lash follicle cultures, hence existing publications on that topic are limited to animal studies. Yet, human scalp hair cultures are common and have been successfully achieved for the past several decades, whereby tissues are obtained during face-lift procedures. A research guide has been proposed to standardize the scalp hair follicle culture, which is of interest to researchers in different fields: experimental dermatology, genetics, developmental biology and endocrinology. It is even possible to observe human hair follicles in vivo with xenotransplantation (the follicles in their anagen phase or full-thickness skin portions are removed from the human scalp and transplanted on the back of mice). All of these studies highlight how hair research has progressed as compared to eyelash research. To overcome this gap, other mammals had to be considered. In the past, primate tissues have been used due to their resemblance with respect to anatomy and physiology. However, animal protection laws have evolved and primates have a restricted accessibility. Previous hair studies have demonstrated that both human and porcine hair follicles are anatomically close. Consequently, preliminary trials on cultivated porcine lash follicles were performed as recently as 2016, whereby follicles from pigs intended for human consumption were used for organ culture assays. An elongation of the follicles was obtained within a few days. Hopefully, this study and future ones will enhance our knowledge on the lash and help to reduce the gap between studies on lashes and hair.

Imaging of lashes

Imaging is a minimally invasive technique to quantify various parameters of human lashes. Observational studies with different age categories demonstrated that lashes change with age. Characteristics such as the orientation, length, thickness and pigmentation were measured from photographs of the lower and upper lids. Human and mouse eyelash life cycle phases have been estimated with photographs in several studies. However, the measures were variable from one study to another due to non-standardized methodologies. To improve accuracy, Thibault et al. observed preselected lashes over a nine-month period by measuring their length each week. Once again, while imaging of lashes estimates the parameters of the life cycle, more advanced techniques described above, such as xenotransplantation and follicle cultures, are routinely used to measure the same parameters for hair.

Imaging techniques have also been utilized for ethnic differences between the lashes of Caucasian and Asian women. Digital photographs were used to calculate the lift-up and curl-up angles of the upper lashes and phototrichogram (allows in vivo study of the growth cycle) for the number, length and thickness of lashes. Smaller lash details such as the cuticle textures and layer density were observed ex vivo with electron microscopy.

Study on aerodynamics

No in vivo studies of human lash aerodynamics exist to date in the literature. Only one in vitro study exists using a model of a mammalian eye to study the aerodynamics of particles around eyelashes. The biophysics research team designed a wind tunnel in which air flow, that could affect the ocular surface, was recreated. The model had dimensions of an adult human eye, with a depth of 4 mm and a diameter of 20 mm, and was made with an aluminum dish. Water filled in the dish was used to mimic the tear film and a mesh was chosen to represent the lashes, after obtaining the same results with commercially available lashes made with human hair. Measurements of water evaporation on the ocular surface and calculation of particle deposition on the lashes were obtained using various mesh lengths. Optimal lash lengths that decreased evaporation and particle deposition were determined. Using fluid mechanic principles, the flow on the model eye’s surface, as well as around and through lashes, were calculated. The optimal lash length determined was compared with other mammalian eyelash lengths, obtained by photographs from phylogenetically diverse preserved mammalian heads. They established that the optimal lash length was one-third of the width of the eye. Aerodynamic analysis confirmed that this was the optimal length, because it reduced tear evaporation and deposition of particles on lashes by half. Short lashes created a zone of airflow stagnation above the ocular surface, while long lashes pushed the airflow toward the ocular surface. These aerodynamic studies highlighted the important role of lashes in the protection of the eye. In vivo studies should be carried out to validate these results on humans, but the wind tunnel effect would most undoubtedly induce an increased frequency of reflex blinking to protect the ocular surface. Based on this study, any alterations of lash length, be it with certain pharmaceuticals or cosmetic procedures (i.e. lash extensions), would have an impact on the protective effect of the ocular surface. Further studies will be needed to validate this impact. Although the study provided an interesting insight into the role that lashes play in the aerodynamics at the front surface of the eye, there remained limitations. Some examples of those include the plane surface used in the model, instead of a convex surface, and water as the chosen composition to represent the tear film, which is more complex in mammals. Studying the protective role of lashes was unexplored before this study, and the authors have paved the way for future investigations in the aerodynamic role of in vivo human lashes.

Pathophysiology of the lashes and their management

Definitions of lash anomalies

During an evaluation of the anterior segment of the eye, ECPs need to assess the normalcy of several structures including eyelashes. There are several terms in the
literature that define anomalies of hair anywhere on the body, however some are specific for eyelashes. Table 1 summarizes the different types of hair anomalies and their associated pathologies.

There is a consensus on most definitions on eyelash anomalies with the exception of hypertrichosis and trichomegaly. The term hypertrichosis is commonly misinterpreted as a synonym for trichomegaly, even though they have distinct definitions. Hypertrichosis is defined as an increase in hair in any part of the body, whereas trichomegaly is specific for eyelashes and eyebrows. The definitions of hypertrichosis and trichomegaly adopted for this review reflect the ones used in recent publications. Also, the terms madarosis and milphosis are often confused. In a clinical setting, the term madarosis is used to describe lash loss, however milphosis is the more appropriate term.

### Management of lash anomalies

The etiology and management of poliosis, trichiasis, milphosis and trichomegaly have been summarized from the written literature, mainly from case reports (Table 2). Depending on the etiology, a single pathology or several lash pathologies may be present simultaneously. As a result of the lack of substantive clinical trials on lash pathologies, Table 2 emphasizes the most frequently reported management strategies, and as such, is non-exhaustive.

It is essential for ECPs to first determine the etiology of the lash pathology to select the appropriate management. In the particular case of milphosis without a clear etiology, ECPs must consider a psychiatric disorder called trichotillomania as a possible causal factor, regardless of the concomitance of eyebrow and/or hair madarosis. Trichotillomania is characterized by an uncontrollable urge to pull out hair from any part of the body and a referral for a psychological evaluation should be considered. This condition can be managed by investigating the cause of the behavior and, in some cases, pharmacotherapy is recommended.

The etiology of the lash pathology also affects the appearance of the lashes, which may affect the patient’s esthetic appearance. For example, common causes of trichomegaly, such as HIV infection and allergic rhinitis, will induce the regrowth of long and smooth lashes, while epidermal growth factor receptor (EGFR) inhibitors make them rougher and more dispersed. The appearance of eyelashes also has a major impact on the quality of life, as hair loss can cause various degrees of psychological distress. Dunnill et al. have demonstrated that the most distressing side effect of chemotherapy is the loss of hair. Other systemic diseases that induce hair loss can be stressful for the affected person, such as alopecia areata, which is characterized by a patchy loss of scalp hair. This disease can progress to other parts of the body, including eyelashes. Although the exact pathophysiological mechanism is not established yet, it is thought to be caused by an autoimmune attack on hair follicles. Patients with alopecia areata have poor health-related quality life scores similar to what is established in other chronic skin diseases, as demonstrated in two systematic studies.

As seen in Table 2, the management of lash pathologies will be influenced by their causal agent. When the lash pathology severity ranges from mild to moderate, this can be managed by an ECP in most cases. To date, there is only one pharmaceutical option approved for eyelash loss (lash hypotrichosis), consisting of a topical application of bimatoprost ophthalmic solution 0.03% (Latisse, Allergan) along the superior lash base. Its mode of action is to prolong the anagen phase of the lash life cycle, hence resulting in an increased lash length, thickness and pigmentation. Before using this product, patients should always seek the advice of an ECP. If adverse events occur, such as discomfort and skin pigmentation, discontinuation of the product will typically reverse the effects. Some cases of poliosis have been reported following prostaglandin analog use.
Table 2 Etiologies and management of lash conditions.

| Pathological condition | Etiology                                                                 | Management                                                                 |
|------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Poliosis               | **Congenital syndromes**<sup>46</sup> | No medication approved to restore lash pigmentation If ophthalmic-related: treat underlying etiology<sup>54</sup> with results varying from no change to full recovery of the pigmentation<sup>67,51,53</sup> |
|                        | **Acquired conditions**<sup>36,47-49</sup>; melanocytic lesions, inflammatory systemic disorders, blepharitis and vernal keratoconjunctivitis (VKC) | If systemic implication<sup>54</sup>: referred to the patient’s primary care doctor |
|                        | **Less common**: systemic/ophthalmic drug-induced (side effect of all topical prostaglandin analogs)<sup>50-53</sup> | Initial episode: epilation of the affected lash(es) and soft contact lenses for short-term relief of induced conjunctival or corneal irritation<sup>55</sup> Recurrent episode: refer to an ophthalmologist for an ablation procedure (depends on the severity): laser argon ablation,<sup>56,57</sup> electrolysis,<sup>58</sup> trephination,<sup>59</sup> direct internal lash bulb extirpation,<sup>60</sup> folliculectomy,<sup>61</sup> cryotherapy,<sup>61</sup> entropion surgery<sup>62</sup> If skin disease suspected: refer to a dermatologist |
| Trichiasis             | **Ophthalmic**<sup>39</sup>; lid margin scars from trauma/surgery; lid margin inflammation; conjunctival diseases; conjunctival burns Various skin diseases<sup>39</sup> | Reversible follicle damage<sup>69</sup>: lash(es) regrowth possible; consider pharmaceutical approach to increase the regrowth rate (bimatoprost ophthalmic solution 0.03% is the only approved drug in patients with healthy lashes and hypotrichosis<sup>65-68</sup> |
|                        | **Irreversible follicle damage**: no lash regrowth | Severe irreversible milphosis: refer to an oculoplastic surgeon for lash grafting consideration<sup>63</sup> |
|                        | **Associated with eyebrow madarosis**<sup>63</sup>: several dermatological diseases and inherited conditions | Severe irreversible milphosis: refer to an oculoplastic surgeon for lash grafting consideration<sup>63</sup> |
|                        | **Associated with eyebrow and hair madarosis**<sup>63</sup>: Extensive list of systemic and drug-induced conditions | Severe irreversible milphosis: refer to an oculoplastic surgeon for lash grafting consideration<sup>63</sup> |
| Milphosis (loss of lashes) | **Ophthalmic**<sup>69</sup>: lid infestation (staphylococcal spp., Demodex folliculorum, trachoma) and/or lid inflammation (posterior blepharitis, ocular rosacea, seborrheic blepharitis) | Trimming of the affected lashes if visual disturbance or smudging with inner surface of eyeglass lens<sup>70-72</sup> With concomitant trichiasis<sup>67</sup>: refer to trichiasis management (above) |
|                        | **Associated with eyebrow and hair madarosis**<sup>63</sup>: Extensive list of systemic and drug-induced conditions | Severe irreversible milphosis: refer to an oculoplastic surgeon for lash grafting consideration<sup>63</sup> |
|                        | **Congenital syndromes**<sup>69</sup>: (Oliver-McFarlane and Cornelia de Lange) Familial | Severe irreversible milphosis: refer to an oculoplastic surgeon for lash grafting consideration<sup>63</sup> |
|                        | **Acquired**<sup>69</sup>: Allergic rhinitis, atopic dermatitis, HIV infection, uveitis and VKC **Drug-induced**<sup>44</sup>: Topical prostaglandin analogs and epidermal growth factor receptor (EGFR) inhibitors used in oncology | Severe irreversible milphosis: refer to an oculoplastic surgeon for lash grafting consideration<sup>63</sup> |

To date, there is no medication approved to restore the pigmentation of lashes. Severe lash pathologies must be referred to specialists for an ablation procedure, lid reconstruction<sup>50,61</sup> or systemic therapies.<sup>78</sup> Promising therapies are emerging for hair loss, which can lead to the discovery of new treatments for eyelashes specifically. Dainichi and Kabashima have reviewed all current therapies and treatments that have an effect on hair regrowth in alopecia areata and universalis (subtype of alopecia that also affect the lashes).<sup>78</sup> In alopecia universalis, hair regrowth has been observed with medications such as topical immunotherapy and corticosteroids.<sup>78</sup> However, these studies focused on scalp hair regrowth and did not collect data on the regrowth rate of lashes. Data from scalp hair studies may guide future therapies for eyelashes.

**Lid margin microflora**

The inherent microflora of the lid margin also plays a vital role in maintaining the lashes free of anomalies. The lid margin typically contains a microflora composed of commensal bacteria and parasites. A disruption of the balance of this microflora can lead to various types of blepharitis.<sup>82</sup> Lee et al. have demonstrated that the most common bacteria found in lash samples were Propionibacterium, Staphylococcus, Streptophyta, Corynebacterium and Enhydrobacter.<sup>83</sup> The variety of the lash microflora is unique to each individual. The study further highlighted that when blepharitis was diagnosed, Staphylococcus, Streptophyta, Corynebacterium, and Enhydrobacter were increased whereas Propionibacterium was decreased. Due to the constant contact of the lids with the ambient air, the lid microflora is particularly influenced by environmental...
factors, such as pollen, dust, and soil particles. Furthermore, touching our lids with our fingers can inoculate other varieties of the microflora, contributing to the dynamic nature of the lid margin microflora.

Bacterial overpopulation can be observed clinically with the presence of debris on the lashes. *Acute Staphylococal* blepharitis is identified with collarettes, which are hard crusts on lashes, and with other non-specific signs (squarescale, telangiectasia vessels, Meibomian gland dysfunction).86 Chronic signs are madarosis, trichiasis, poliosis, tylosis or scars on the lid margin.82,84 Blepharitis can also be caused by other micro-organisms, such as parasites. Three types of parasites, all arthropods, can inhabit the lid margin: *Demodex follicularum*, *Demodex brevis* and *Phthirius pubis*.85 *Demodex* parasites are part of the natural eyelash microflora82 and their number increases with age, so much so that one study has reported 100% prevalence in people over 70 years old.86 *D. folliculorum* is mostly found in the lash follicle and other parts of the body such as eyebrows, scalp, nose and ears. *D. brevis* is found mainly in the Meibomian glands and other sebaceous glands, such as the face.87 The anatomy of the *Demodex* parasite consists of a head with four pairs of legs on either side and an elongated body/tail that contains the digestive system. The parasite has no anus, hence all the ingested material remains in the gut, along with its own microflora of *Streptococcus* spp., *Staphylococcus* spp. and *Bacillus oleronius*.88 At the end of its life cycle, approximately 15–18 days in length, the parasite bursts and releases its content, which can provoke an inflammatory response.87,88 An overpopulation of the parasite is called a demodicosis, and on the lids, this would be termed blepharitis secondary to *Demodex*. Since *Demodex* has the potential to affect both the anterior (lashes) and posterior (Meibomian glands) portion of the lid margin, some89 have proposed the term marginal blepharitis to describe a demodicosis of the lid margin. Clinical signs of demodicosis include follicular hypertrophy,97 gelatinous debris surrounding the base of the lashes termed cylindrical dandruff,98 and non-specific blepharitis signs as stated above. Cylindrical dandruff is a pathognomonic sign for *Demodex*.90 On the other hand, the parasite *Phthirius pubis* is not found in the normal lid microflora, as it originates in pubic hair. It can be transmitted by sexual contact and less often through linens and bedding.91 Transfer of the parasite from the infested region to the hand can reach any hair on the body, including the eyelashes.92 The resulting blepharitis is termed *Phthiriasis palpebrarum* and its clinical presentation, in one or both eyes, includes the translucent parasite’s body firmly attached to lashes, brown scales corresponding to the parasite’s fces, and multiple nits (unhatched parasites) fixed on the lashes and the lid margin.91,92 Symptoms include itchiness and irritation of the lid margin.91

Finally, blepharitis can be the result of seborrheic dermatitis, a dermatological condition affecting the skin and in some cases, the lid margin. Many etiologies have been proposed and researchers are still looking for the exact mechanism.93 An imbalance in the skin micro-organisms might be the cause.93 Other than the non-specific signs of blepharitis detailed above, ECPs can observe some flaky scales on the lids that can fall on the lashes.94 When the condition affects the anterior portion of the lid, it is called seborrheic blepharitis.

Management of anterior blepharitis

The aim in blepharitis management is to restore the normal microflora.95 A complete eradication of *Phthiriasis palpebrarum* is desired and can be achieved by mechanical removal of the parasites and nits.95,96 Blepharitis secondary to the imbalance of the microflora are chronic conditions. Hence, they are not expected to be completely eradicated. First line therapies of blepharitis include warm compresses to soften the debris and eyelid hygiene to manually dislodge them.97 Targeted lid margin therapies should be adopted by ECPs, including antibacterial for *Staphylococcal* infestation97 and anti-parasitic formulations for *Demodex* parasites,96,97 in order to limit lid margin anomalies that come with chronic blepharitis. To target properly seborrheic blepharitis, a reference to dermatology is required to establish the diagnosis of seborrheic dermatitis and treat the affected skin with the appropriate pharmaceutical.91

ECP assessment of lashes

Fig. 4 summarizes in a flowchart the management of debris on eyelashes. This tool can be used when teaching students or residents to identify and localize debris on lashes and select the appropriate management.

Iatrogenic factors

The appearance of eyelashes is an increasingly growing pre-occupation in many people who are seeking an esthetic enhancement. Cosmetics have been used since biblical times to improve the esthetic of the eye and the thickness, length and color of eyelashes.100 Lash tints and extensions are newer and popular, surpassing expectations in the cosmetic marketplace. Over $55 million in 2014 were dedicated to eyelash extension and adhesives alone in the US.101 Synthetic lashes are glued individually on the natural lashes with different adhesives, which have been linked to ocular problems such as keratoconjunctivitis.102 In most cases, the glue and removing agents have induced inflammation on the eye, by direct contact with the ocular surface. Furthermore, the vapors associated with the application, or the dissolving, of the glue afterwards have been reported as ocular irritants. Lash tinting is done with dyes that contain p-phenylenediamine, a sensitizer that can provoke an allergic reaction and contact dermatitis.103,104 Water-based mascara is made of several waxes, types of pigment and resins dissolved in water, whereas solvent-based mascara, known as waterproof, has its pigments and waxes added in petroleum distillates.105 Fukami et al. found a positive correlation between the frequency of mascara use and the degree of cracking in the lash cuticles.105 Also, long-term use of mascara led to miliphosis, possibly due to the rubbing, with fingers and water only, by the users.106 Needless to say, eye cosmetics in general can have an impact on the lids, lashes, tear film and ocular surface.107 Consequently, patients need to be educated appropriately about the application, removal, shelf life and associated precautions of cosmetic use.
Conclusion

This review brings a deeper awareness on the eyelashes and their follicles. The current literature has numerous cases of how lashes are affected by systemic/eye diseases, pharmaceuticals and cosmetics, and how they change the lash morphology. In addition, an imbalance of the lash microenvironment can lead to a variety of blepharitis and impact negatively the adjoining lid margin. Many studies have demonstrated that lashes do not serve only a cosmetic function, but also a protective role on the lid margin and the ocular surface. The lash follicle structures are mostly studied with ex vivo techniques, which are limited by the poor availability of the human lid sampling. This review further highlights the challenges when studying the lash follicle and the need to develop newer techniques. Increasing lash research will certainly improve the efficiency of ECP’s interventions in lash anomalies.
Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

SA has received honorarium for conferences/consulting from Allergan and Shire. EB has received funding from Alcon, Allergan, Canadian Optometric Trust Fund, I-Med Pharma Inc, Shire and honorarium for conferences/consulting from Akorn, Alcon, Allergan, American Academy of Optometry, Canadian Association of Optometry, CooperVision, Labtician, Jobson Publishing, Novartis, Santen, Shire.

Acknowledgement

A special thanks to Micheline Gloin for her graphic assistance.

References

1. Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthet Plast Surg. 2011;35:116–121.
2. Draelos ZK. Eye cosmetics. Dermatol Clin. 1991;9:1–7.
3. Montagna W, Ford DM. Histology and cytochemistry of human skin 3. The eyelid. Arch Dermatol. 1969;100:328–335.
4. Willcox MDP, Argueso P, Georgiev GA, et al. TFOS DEWS II Tear Film Report. Ocul Surf. 2017;15:366–403.
5. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276–283.
6. Lioret S, Riera M, Nguyen NH. Les cils. Physiologie, structure, pathologie. Arch Ophtalmol (Paris). 1977;37:697–708.
7. Na Ji, Kwon OS, Kim BJ, et al. Ethnic characteristics of eyelashes: a comparative analysis in Asian and Caucasian females. Br J Dermatol. 2006;155:1170–1176.
8. Marieb E. Le système tégumentaire. In: ERPI, ed. Anatomie et physiologie humaines. 3rd ed. 2005:156–208.
9. Thibault S, De Becker E, Caisey L, et al. Human eyelash characterization. Br J Dermatol. 2010;162:304–310.
10. Smith KR, Thiboutot DM. Thematic review series: skin lipids. Sebaceous gland lipids: friend or foe? J Lipid Res. 2008;49:271–281.
11. Stoeckelhuber M, Stoeckelhuber BM, Welsch U. Human glands of Moll: histochemical and ultrastructural characterization of the glands of Moll in the human eyelid. J Invest Dermatol. 2003;121:28–36.
12. Kloepper JE, Sugawara K, Al-Nuaimi Y, Gaspar E, van Beek N, Paus R. Methods in hair research: how to objectively distinguish between anagen and catagen in human hair follicle organ culture. Exp Dermatol. 2010;19:305–312.
13. Paus R, Burgoa T, Platt CI, Griffiths T, Poblet E, Izeta A. Biology of the eyelash hair follicle: an enigma in plain sight. Br J Dermatol. 2016;174:741–752.
14. Nesher R, Mirmouni M, Elnaddaf H, Nemet A, Kidron D. Characterization of prostaglandin F2alpha receptors in human eyelids. Eur J Ophthalmol. 2015;25:81–84.
15. Thibaut S, Gaillard O, Bouhanna P, Cannelle DW, Bernard BA. Human hair shape is programmed from the bulb. Br J Dermatol. 2005;152:632–638.
16. Thibaut S, Barbarat P, Leroy F, Bernard BA. Human hair keratin network and curvature. Int J Dermatol. 2007;46:7–10.
17. Commo S, Gaillard O, Thibaut S, Bernard BA. Absence of TRPV-2 in melanogenic melanocytes of human hair. Pigment Cell Res. 2004;17:488–497.
18. Schallreuter K, Slominski A, Pawelek JM, Jimbow K, Gilchrest BA. What controls melanogenesis? Exp Dermatol. 1998;7:143–150.
19. Commo S, Gaillard O, Bernard BA. Human hair greying is linked to a specific depletion of hair follicle melanocytes affecting both the bulb and the outer root sheath. Br J Dermatol. 2004;150:435–443.
20. Tobin DJ. Human hair pigmentation – biological aspects. Int J Cosmet Sci. 2008;30:233–257.
21. Arck PC, Overall R, Spatz K, et al. Towards a “free radical theory of graying”: melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage. FASEB J. 2006;20:1567–1569.
22. Prociunay F, Mendonca TB, Bins CA, Lang MP. Characterization of normal mediolateral angular direction of lower eyelid eyelashes in different age groups. Ophthalmic Plast Reconstr Surg. 2015;31:332–333.
23. Glaser DA, Jones D, Carruthers J, et al. Epidemiologic analysis of change in eyelash characteristics with increasing age in a population of healthy women. Dermatol Surg. 2014;40:1208–1213.
24. Harries MJ, Meyer K, Chaudhry I, et al. Lichen planopilaris is characterized by immune privilege collapse of the hair follicle’s epithelial stem cell niche. J Pathol. 2013;231:236–247.
25. Philpott MP, Green MR, Kealey T. Human hair growth in vitro. J Cell Sci. 1990;97(Pt 3):463–471.
26. Langan EA, Philpott MP, Kloepper JE, Paus R. Human hair follicle organ culture: theory, application and perspectives. Exp Dermatol. 2015;24:903–911.
27. Hashimoto T, Kazama T, Ito M, et al. Histologic and cell kinetic characterization of prostaglandin F2alpha receptors in human eyelashes: an enigma in plain sight. Br J Dermatol. 2003;149:217–221.
28. Gilhar A, Keren A, Paus R. A new humanized mouse model for alopecia areata. J Investig Dermatol Symp Proc. 2013;16:537–538.
29. Oh JW, Kloepper J, Langan EA, et al. A guide to studying human hair follicle cycling in vivo. J Invest Dermatol. 2016;136:34–44.
30. Weatherall D, Munn H. Moving the primate debate forward. Science. 2007;316:173.
31. Debeer S, Le Luduec JB, Kaiserlian D, et al. Comparative histology and immunohistochemistry of porcine versus human skin. Eur J Dermatol. 2013;23:456–466.
32. Mangelsdorf S, Vergou T, Sterry W, Lademann J, Patzelt A. Comparative study of hair follicle morphology in eight mammalian species and humans. Skin Res Technol. 2014;20:147–154.
33. Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lutjen-Drecoll E. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost. Br J Dermatol. 2010;162:1186–1197.
34. Dhurat R, Phototrichogram. Indian J Dermatol Venereol Leprol. 2006;72:242–244.
35. Amador GJ, Mao W, DeMercurio P, et al. Eyelashes divert airflow to protect the eye. J R Soc Interface. 2015;12.
36. Seiler N, Kurfürst B, Schorr A, Bank S. Poliosis circumscripta: overview and underlying causes. J Am Acad Dermatol. 2013;69:625–633.
37. Meyer KC, Brzoska T, Abels C, Paus R. The alpha-melanocyte stimulating hormone-related tripeptide K(D)PT stimulates human hair follicle pigmentation in situ under proinflammatory conditions. Br J Dermatol. 2009;160:433–437.
38. Dutton JJ, Tawfik HA, DeBacker CM, Lipham WJ. Direct internal eyelash bulb extirpation for trichiasis. Ophthalmic Plast Reconstr Surg. 2000;16:142–145.

39. Ferreira IS, Bernardes TF, Bonfili AA. Trichiasis. Semin Ophthalmol. 2010;25:66–71.

40. Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349–358.

41. Vij A, Bergfeld WF. Madarosis, milphosis, eyelash trichomegaly, and dermatotrichoscopy. Clin Dermatol. 2015;33:217–226.

42. Wendelin DS, Pope DN, Mallory SB. Hypertrichosis. J Am Acad Dermatol. 2003;48:161–182.

43. Ferreira IS, Bernardes TF, Bonfioli AA. Trichiasis. Dermatol Surg. 2007;33:265–271.

44. Paul LJ, Cohen PR, Kurzrock R. Eyelash trichomegaly: a clinical and histopathologic evaluation. J Am Acad Dermatol. 2004;51:631–646, 643–634, 646.

45. Santmyre-Rosenberger BR, Albert M. Acquired trichomegaly, and apparent hypotrichosis on its withdrawal. Ophthal Clin North Am. 2007;20(1):95–104.

46. Santmyre-Rosenberger BR, Albert M. Acquired trichomegaly: a clinical and histopathologic evaluation. J Am Acad Dermatol. 2004;51:631–646, 643–634, 646.

47. TabbaraKF. Reversal of poliosis and vitiligo following Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2012;90(5):e394–396.

48. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265–292.

49. Kumar S, Al Khars W. Vitiligo in association with vernal keratoconjunctivitis. Saudi J Ophthalmol. 2016;30:128–129.

50. Nakakura S, Yamamoto M, Terao E, et al. Prostaglandin-associated perilobitispathy in latanoprost users. Clin Ophthalmol. 2015;9:51–56.

51. Chen CS, Wills J, Craig JE. Topical prostaglandin F(2alpha) analog induced poliosis. Am J Ophthalmol. 2004;137:965–966.

52. Ozurt S, Cetinkaya GS. Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost. Actas Dermosifiliogr. 2015;106:74–75.

53. Waheed K, Laganowski H. Bilateral poliosis and granulomatous anterior uveitis associated with latanoprost use and apparent hypotrichosis on its withdrawal. Eye (Lond). 2001;15:347–349.

54. Jalalat SZ, Kelsoe JR, Cohen PR. Alopecia areata with white hair regrowth: case report and review of poliosis. Dermatol Online J. 2014;20.

55. Chlou AGY, Florakis GJ, Kazim M. Management of conjunctival cicatrizating diseases and severe ocular surface dysfunction. Surv Ophthalmol. 1998;43:19–46.

56. Yung CW, Massicotte SJ, Kuwabara T. Argon laser treatment of trichiasis: a clinical and histopathologic evaluation. Ophthalmic Plast Reconstr Surg. 1994;10:130–136.

57. Basar E, Ozdemir H, Ozkan S, Cicik E, Mirzatav C. Treatment of trichiasis with argon laser. Eur J Ophthalmol. 2000;10:273–275.

58. Benson A. On the treatment of partial trichiasis by electrolysis. Br Med J. 1882;2:1203–1204.

59. McCracken MS, Kikkawa DO, Vasani SN. Treatment of trichiasis and distichiasis by eyelash trephination. Ophthalmic Plast Reconstr Surg. 2006;22:349–351.

60. Tirakunwichacha S, Tinnangwattana U, Hiranwiwatkul P, Rohipopakarn S. Folliculcectomy: management in segmental trichiasis and distichiasis. J Med Assoc Thai. 2006;89:90–93.

61. Elder MJ, Bernauer W. Cryotherapy for trichiasis in ocular cicatricial pemphigoid. Br J Ophthalmol. 1994;78:769–771.

62. Ballen PH. A simple procedure for the relief of trichiasis and entropion of the upper lid. Arch Ophthalmol. 1964;72:239–240.

63. Kumar A, Kharthikeyan K. Madarosis: a marker of many maladies. Int J Trichol. 2012;4:3–18.

64. Khong JJ, Casson RJ, Hullgo SC, Selva D. Madarosis. Surv Ophthalmol. 2006;51:550–560.

65. Barron-Hernandez YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26:515–522.

66. Zaleski-Larsen LA, Ruth NH, Fabi SG. Retrospective evaluation of topical bimatoprost and iris pigment change. Dermatol Surg. 2017.

67. Smith S, Fagien S, Whitcup SM, et al. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2012;66:801–806.

68. Fagien S. Management of hypotrichosis of the eyelashes: focus on bimatoprost. Clin Cosmet Investig Dermatol. 2010;3:39–48.

69. Kaur S, Mahajan BB. Eyelash trichomegaly. Indian J Dermatol. 2015;60:378–380.

70. Lacourt ME, Boerma SR, Lorusso PM. Non-rash skin toxicities associated with novel targeted therapies. Clin Lung Cancer. 2006;8(suppl 1):S36–S42.

71. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491–500.

72. Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol. 2003;42:345–346.

73. Christenson GA, Popkin MK, Mackenzie TB, Realmuto GM. Lithium treatment of chronic hair pulling. J Clin Psychiatry. 1991;52:116–120.

74. Johnson J, El-Alfy AT. Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania. J Adv Res. 2016;7:169–184.

75. Phillips TG, Slomiany WP, Allison R. Hair loss: common causes and treatment. Am Fam Physician. 2017;96:371–378.

76. Dunnill CJ, Al-Tameemi W, Collett A, Haslam IS, Georgopoulos NT. A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. Oncologist. 2017.

77. Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75:806–812, e803.

78. Dainichi T, Kabashima K. Alopecia areata: what’s new in epidemiology, pathogenesis, diagnosis, and therapeutic options? J Dermatol Sci. 2017;86:3–12.

79. Rencz F, Gulaci S, Pentek M, Wkonkol N, Bajaj P, Brodzky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175:561–571.

80. Khafagy A, Mostafa MM, Fooshan F. Management of trichiasis with lid margin split and cryotherapy. Clin Ophthalmol. 2012;6:1815–1817.

81. Choo PH. Distichiasis, trichiasis, and entropion: advances in management. Int Ophthalmol Clin. 2002;42:75–87.

82. Nicholls SG, Oakley CL, Tan A, Vote BJ. Demodex species in human ocular disease: new clinicopathological aspects. Int Ophthalmol. 2017;37:303–312.

83. Lee SH, Oh DH, Jung JY, Kim JC, Jeon CO. Comparative ocular microbial communities in humans with and without blepharitis. Invest Ophthalmol Vis Sci. 2012;53:5585–5593.

84. Bernardes TF, Bonfili AA. Blepharitis. Semin Ophthalmol. 2010;25:79–83.
85. Padhi TR, Das S, Sharma S, et al. Ocular parasites: a comprehensive review. *Surv Ophthalmol*. 2017;62:161-189.
86. Roth AM. *Demodex folliculorum* in hair follicles of eyelid skin. *Ann Ophthalmol*. 1979;11:37-40.
87. Liu J, Sheha H, Tseng SC. Pathogenic role of *Demodex* mites in blepharitis. *Curr Opin Allergy Clin Immunol*. 2010;10:505-510.
88. Szkaradkiewicz A, Chudzicka-Strugala I, Karpinski TM, et al. *Bacillus oleronius* and *Demodex* mite infestation in patients with chronic blepharitis. *Clin Microbiol Infect*. 2012;18:1020-1025.
89. Duncan K, Jeng BH. Medical management of blepharitis. *Curr Opin Ophthalmol*. 2015;26:289-294.
90. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of *Demodex* in eyelashes with cylindrical dandruff. *Invest Ophthalmol Vis Sci*. 2005;46:3089-3094.
91. Anane S, Malek I, Kamoun R, Chtourou O. *Phthiriasis palpebrarum*: diagnosis and treatment. *J Fr Ophtalmol*. 2013;36:815-819.
92. Turgut B, Kurt J, Catak O, Demir T. *Phthiriasis palpebrarum* mimicking lid eczema and blepharitis. *J Ophthalmol*. 2009;2009:803951.
93. Paulino LC. New perspectives on dandruff and seborrheic dermatitis: lessons we learned from bacterial and fungal skin microbiota. *Eur J Dermatol*. 2017;27:4-7.
94. Wolf R, Orion E, Tuzun Y. Periorbital (eyelid) dermatides. *Clin Dermatol*. 2014;32:131-140.
95. Nicholls SG, Oakley CL, Tan A, Vote BJ. *Demodex* species in human ocular disease: new clinicopathological aspects. *Int Ophthalmol*. 2016.
96. Dagdelen S, Aykan U, Cetinkaya K. *Phthiriasis palpebrarum* can resemble tick larva infestation in an eyelid. *J AAPOS*. 2013;17:440-442.
97. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. *Cochrane Database Syst Rev*. 2012:CD005556.
98. Gao YY, Di Pascuale MA, Li W, et al. In vitro and in vivo killing of ocular *Demodex* by tea tree oil. *Br J Ophthalmol*. 2005;89:1468-1473.
99. Ngo W, Jones L, Bitton E. Short-term comfort responses associated with the use of eyelid cleansing products to manage *Demodex folliculorum*. *Eye Contact Lens*. 2017.
100. Draelos ZD. Special considerations in eye cosmetics. *Clin Dermatol*. 2001;19:424-430.
101. Statista. Annual sales of the leading false eyelashes and adhesives in the United States in 2014 (in million U.S. dollars); 2017.
102. Amano Y, Sugimoto Y, Sugita M. Ocular disorders due to eyelash extensions. *Cornea*. 2012;31:121-125.
103. Teixeira M, de Wachter L, Ronsyn E, Goossens A. Contact allergy to para-phenylenediamine in a permanent eyelash dye. *Contact Dermatitis*. 2006;55:92-94.
104. Ali L, Foulds JS, Abdul Ghaffar S. Severe eyelid allergic contact dermatitis secondary to eyelash tint: two case reports. *Contact Dermatitis*. 2017;77:59-60.
105. Fukami K, Inoue T, Kawai T, Takeuchi A, Uesugi K, Suzuki Y. Internal structure changes of eyelash induced by eye makeup. *J Cosmet Sci*. 2014;65:217-224.
106. Kadri R, Achar A, Tantry TP, Parameshwar D, Kudva A, Hegde S. Mascara induced milphosis, an etiological evaluation. *Int J Trichol*. 2013;5:144-147.
107. Ng A, Evans K, North RV, Jones L, Purslow C. Impact of eye cosmetics on the eye adnexa, and ocular surface. *Eye Contact Lens*. 2016;42:211-220.